{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.68","upperLimit":"0.82","value":"0.746"},{"groupId":"OG001","lowerLimit":"0.51","upperLimit":"0.70","value":"0.607"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"124"}],"units":"Participants"}],"description":"EFS between centrally reviewed differentiated ependymoma and anaplastic ependymoma for the patients who were treated with radiation therapy only. The event-free survival (EFS) defined as the time to disease progression, disease relapse, occurrence of a second neoplasm, or death from any cause, measured from the start of radiation therapy. The product-limit (Kaplan-Meier) estimate is for estimation of EFS probability at 5 years.","dispersionType":"95% Confidence Interval","groups":[{"description":"Differentiated ependymoma:tumor pathology by central review.","id":"OG000","title":"Differentiated Ependymoma"},{"description":"Anaplastic ependymoma:tumor pathology by central review.","id":"OG001","title":"Anaplastic Ependymoma"}],"paramType":"NUMBER","populationDescription":"Supratentorial Anaplastic Ependymoma (GTR1, GTR2, NTR) and Anaplastic or Differentiated Infratentorial Ependymoma (GTR1, GTR2, NTR) and Supratentorial Differentiated Ependymoma(GTR2, NTR). Patients undergo conformal radiation therapy to the brain once daily 5 days a week for 6-6½ weeks.","reportingStatus":"POSTED","timeFrame":"At 5 years since the time of radiation therapy","title":"Event-free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"Probability of EFS at 5 years"}